New combo therapy aims to shrink lung tumors before local treatment
NCT ID NCT07573696
First seen May 09, 2026 · Last updated May 16, 2026 · Updated 2 times
Summary
This study tests whether giving a targeted drug (alectinib) plus chemotherapy before surgery or radiation can help people with a specific type of advanced lung cancer (ALK-positive, stage III) that cannot be removed right away. About 50 adults who have not had prior cancer treatment will receive the drug combo for 3 cycles, then a team of doctors will decide if surgery or radiation is best. After local treatment, some may continue alectinib for up to 2 years to keep the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONSMALL CELL LUNG CANCER STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.